DTIL Files 8-K on Officer/Director Changes & Compensation
Ticker: DTIL · Form: 8-K · Filed: Jan 23, 2024 · CIK: 1357874
| Field | Detail |
|---|---|
| Company | Precision Biosciences Inc (DTIL) |
| Form Type | 8-K |
| Filed Date | Jan 23, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.000005 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-governance, executive-changes, compensation
TL;DR
**DTIL just filed an 8-K about leadership changes and pay, keep an eye on it.**
AI Summary
Precision BioSciences, Inc. (DTIL) filed an 8-K on January 23, 2024, reporting that the earliest event occurred on January 22, 2024. This filing indicates a current report regarding the departure or election of directors or officers and their compensatory arrangements, as well as financial statements and exhibits. For investors, this matters because changes in leadership or executive compensation can signal shifts in company strategy, financial health, or future performance, potentially impacting stock valuation.
Why It Matters
Changes in executive leadership or compensation can significantly influence a company's strategic direction and operational efficiency, directly affecting investor confidence and stock performance.
Risk Assessment
Risk Level: medium — Changes in leadership can introduce uncertainty, but the specific details of the changes are not yet fully disclosed, making the immediate impact unclear.
Analyst Insight
A smart investor would monitor subsequent filings or company announcements for specific details regarding the personnel changes and compensatory arrangements to assess their potential impact on the company's future direction and financial health.
Key Players & Entities
- Precision BioSciences, Inc. (company) — the registrant filing the 8-K
- DTIL (company) — the trading symbol for Precision BioSciences, Inc.
- The Nasdaq Capital Market (company) — the exchange where DTIL common stock is registered
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 22, 2024.
What specific items are covered in this 8-K filing?
This 8-K filing covers 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' and 'Financial Statements and Exhibits'.
What is the trading symbol and exchange for Precision BioSciences, Inc. common stock?
The trading symbol for Precision BioSciences, Inc. common stock is DTIL, and it is registered on The Nasdaq Capital Market.
When was this 8-K filed with the SEC?
This 8-K was filed with the SEC on January 23, 2024.
What is the address of Precision BioSciences, Inc.'s principal executive offices?
The address of Precision BioSciences, Inc.'s principal executive offices is 302 East Pettigrew St. Suite A-100, Durham, North Carolina, 27701.
Filing Stats: 860 words · 3 min read · ~3 pages · Grade level 12.5 · Accepted 2024-01-23 17:29:47
Key Financial Figures
- $0.000005 — ch registered Common Stock, par value $0.000005 per share DTIL The Nasdaq Capital M
Filing Documents
- dtil-20240122.htm (8-K) — 52KB
- dtil-ex10_1.htm (EX-10.1) — 142KB
- dtil-ex10_2.htm (EX-10.2) — 136KB
- dtil-ex10_3.htm (EX-10.3) — 136KB
- dtil-ex10_4.htm (EX-10.4) — 136KB
- img72316305_0.jpg (GRAPHIC) — 8KB
- img73239826_0.jpg (GRAPHIC) — 8KB
- img74163347_0.jpg (GRAPHIC) — 8KB
- img75086868_0.jpg (GRAPHIC) — 8KB
- 0000950170-24-006661.txt ( ) — 788KB
- dtil-20240122.xsd (EX-101.SCH) — 27KB
- dtil-20240122_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Executive Employment Agreement, dated January 22, 2024, by and between Michael Amoroso and Precision BioSciences, Inc. 10.2 Executive Employment Agreement, dated January 22, 2024, by and between Alex Kelly and Precision BioSciences, Inc. 10.3 Executive Employment Agreement, dated January 22, 2024, by and between Dario Scimeca and Precision BioSciences, Inc. 10.4 Executive Employment Agreement, dated January 22, 2024, by and between Jeff Smith and Precision BioSciences, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PRECISION BIOSCIENCES, INC. Date: January 23, 2024 By: /s/ Dario Scimeca Dario Scimeca General Counsel